Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Compellis wins second US patent for new obesity therapy
The patent broadly protects key aspects of Compellis’ novel obesity therapeutic strategy. CP404 is a calcium channel blocker used in a nasal formulation to block olfactory activity and
The patent broadly protects key aspects of Compellis’ novel obesity therapeutic strategy. CP404 is a calcium channel blocker used in a nasal formulation to block olfactory activity and
The randomized, placebo-controlled, third-party double-blind, dose escalating Phase I clinical trial will study Protexia administered intramuscularly at one and two time points in healthy human volunteers. Approximately 32
The pharmaceutical development and quality analysis (PDQ) product line consists of products used for drug content uniformity and dissolution rate testing and related services. The sale is expected
Mr Handler will drive the continued development and subsequent commercialization of the company’s innovative vascular robotic system. Before joining Corindus, Mr Handler spent more than 20 years at
Under the terms of the agreement, a subsidiary of GlaxoSmithKline (GSK) will commence a tender offer to acquire all of the outstanding shares of Genelabs common stock. The
The acquisition follows an exclusive license of the diabody IP that Affitech obtained in 2007 from Pharmexa to carry out certain non-clinical good laboratory practice compliant studies, as
Dr Polisky replaces Steven Quay, chief scientific officer, chairman of the board of directors and chairman of the scientific advisory board, who will be leaving the company on
These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer’s disease and cognitive
LoSeasonique is the first lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy, said Barr. Under the LoSeasonique extended-cycle regimen, women take combination tablets containing 0.10mg levonorgestrel/0.02mg
Under the terms of the license agreement, BioWa grants KaloBios non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through Potelligent technology for an undisclosed number of